Verughese Jacob1, Jeffrey A Reynolds2, Sajal K Chattopadhyay3, David P Hopkins3, Nicole L Therrien4, Christopher D Jones5, Jeffrey M Durthaler5, Kimberly J Rask6, Alison E Cuellar7, John M Clymer8, Thomas E Kottke9. 1. The Community Guide Office, Office of the Associate Director for Policy and Strategy, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: hir0@cdc.gov. 2. The Community Guide Office, Office of the Associate Director for Policy and Strategy, Centers for Disease Control and Prevention, Atlanta, Georgia; Cherokee Nation Assurance LLC, Catoosa, Oklahoma. 3. The Community Guide Office, Office of the Associate Director for Policy and Strategy, Centers for Disease Control and Prevention, Atlanta, Georgia. 4. ASRT, Inc., Smyrna, Georgia; Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. 5. Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. 6. Alliant Health Solutions, Atlanta, Georgia. 7. Department of Health Administration and Policy, College of Health and Human Services, George Mason University, Fairfax, Virginia. 8. National Forum for Heart Disease & Stroke Prevention, Washington, District of Columbia. 9. HealthPartners Institute, Bloomington, Minnesota.
Abstract
INTRODUCTION: Adherence to medications for cardiovascular disease and its risk factors is less than optimal, although greater adherence to medication has been shown to reduce the risk factors for cardiovascular disease. This paper examines the economics of tailored pharmacy interventions to improve medication adherence for cardiovascular disease prevention and management. METHODS: Literature from inception of databases to May 2019 was searched, yielding 29 studies for cardiovascular disease prevention and 9 studies for cardiovascular disease management. Analyses were done from June 2019 through May 2020. All monetary values are in 2019 U.S. dollars. RESULTS: The median intervention cost per patient per year was $246 for cardiovascular disease prevention and $292 for cardiovascular disease management. The median change in healthcare cost per person per year due to the intervention was -$355 for cardiovascular disease prevention and -$2,430 for cardiovascular disease management. The median total cost per person per year was -$89 for cardiovascular disease prevention, with a median return on investment of 0.01. The median total cost per person per year for cardiovascular disease management was -$1,080, with a median return on investment of 7.52, and 6 of 7 estimates indicating reduced healthcare cost averted exceeded intervention cost. For cardiovascular disease prevention, the median cost per quality-adjusted life year gained was $11,298. There were no cost effectiveness studies for cardiovascular disease management. DISCUSSION: The evidence shows that tailored pharmacy-based interventions to improve medication adherence are cost effective for cardiovascular disease prevention. For cardiovascular disease management, healthcare cost averted exceeds the cost of implementation for a favorable return on investment from a healthcare systems perspective. Published by Elsevier Inc.
INTRODUCTION: Adherence to medications for cardiovascular disease and its risk factors is less than optimal, although greater adherence to medication has been shown to reduce the risk factors for cardiovascular disease. This paper examines the economics of tailored pharmacy interventions to improve medication adherence for cardiovascular disease prevention and management. METHODS: Literature from inception of databases to May 2019 was searched, yielding 29 studies for cardiovascular disease prevention and 9 studies for cardiovascular disease management. Analyses were done from June 2019 through May 2020. All monetary values are in 2019 U.S. dollars. RESULTS: The median intervention cost per patient per year was $246 for cardiovascular disease prevention and $292 for cardiovascular disease management. The median change in healthcare cost per person per year due to the intervention was -$355 for cardiovascular disease prevention and -$2,430 for cardiovascular disease management. The median total cost per person per year was -$89 for cardiovascular disease prevention, with a median return on investment of 0.01. The median total cost per person per year for cardiovascular disease management was -$1,080, with a median return on investment of 7.52, and 6 of 7 estimates indicating reduced healthcare cost averted exceeded intervention cost. For cardiovascular disease prevention, the median cost per quality-adjusted life year gained was $11,298. There were no cost effectiveness studies for cardiovascular disease management. DISCUSSION: The evidence shows that tailored pharmacy-based interventions to improve medication adherence are cost effective for cardiovascular disease prevention. For cardiovascular disease management, healthcare cost averted exceeds the cost of implementation for a favorable return on investment from a healthcare systems perspective. Published by Elsevier Inc.
Authors: S L Ellis; B L Carter; D C Malone; S J Billups; G J Okano; R J Valuck; D J Barnette; C D Sintek; D Covey; B Mason; S Jue; J Carmichael; K Guthrie; R Dombrowski; D R Geraets; M Amato Journal: Pharmacotherapy Date: 2000-12 Impact factor: 4.705
Authors: C López Cabezas; C Falces Salvador; D Cubí Quadrada; A Arnau Bartés; M Ylla Boré; N Muro Perea; E Homs Peipoch Journal: Farm Hosp Date: 2006 Nov-Dec
Authors: Janice L Pringle; Annette Boyer; Mark H Conklin; Jesse W McCullough; Arnie Aldridge Journal: Health Aff (Millwood) Date: 2014-08 Impact factor: 6.301
Authors: Meera Viswanathan; Carol E Golin; Christine D Jones; Mahima Ashok; Susan Blalock; Roberta C M Wines; Emmanuel J L Coker-Schwimmer; Catherine A Grodensky; David L Rosen; Andrea Yuen; Priyanka Sista; Kathleen N Lohr Journal: Evid Rep Technol Assess (Full Rep) Date: 2012-09
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Ileana L Piña; Katherine E Di Palo; Marie T Brown; Niteesh K Choudhry; Jamie Cvengros; Deborah Whalen; Laurie P Whitsel; Janay Johnson Journal: Prog Cardiovasc Dis Date: 2020-08-12 Impact factor: 8.194